Remission in schizophrenia: Validity, frequency, predictors, and patients' perspective 5 years later;La remisión en la esquizofrenia: Validez, frecuencia, predictores y percepción de los pacientes después de cinco años

Dialogues in Clinical Neuroscience

Volumn 12, Issue 3, 2010, Pages 393-407

  Lambert, Martin ^a   Karow, Anne ^a   Leucht, Stefan ^b   Schimmelmann, Benno G ^c   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Frequency; Predictor; Remission; Schizophrenia

Indexed keywords

ARTICLE; BEHAVIOR; BODY EQUILIBRIUM; CLINICAL TRIAL; COGNITION; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DISORIENTATION; FUNCTIONAL STATUS; HALLUCINATION; HEALTH STATUS; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; MORBIDITY; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PSYCHIATRIST; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; THOUGHT DISORDER; VOCATION; LONGITUDINAL STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RECURRENT DISEASE; REPRODUCIBILITY; REVIEW;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; LONGITUDINAL STUDIES; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 78049506541     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
2. Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remis-sion. J Psychopharmacol. 2006;20(6 suppl):57-61.
3. Lasser RA, Nasrallah H, Helldin L, et al. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res. 2007;96:223-231.
4. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizo-phrenia: recommendations for their use and their presentation. Acta Psychiatr Scand (suppl). 2009;438:7-14.
5. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 2006;113:91-95.
6. Sethuraman G, Taylor CC, Enerson M, et al. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res. 2005;79:337-340.
7. Dunayevich E, Sethuraman G, Enerson M, et al. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res. 2006;86:300-308.
8. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
9. van Os J, Drukker M, à Campo J, et al. Validation of remission criteria for schizophrenia. Am J Psychiatry. 2006;163:2000-2002.
10. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl). 2007;194:453-461.
11. Liberman R, Kopelowicz A, Ventura J, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14:256-272.
12. Beitinger R, Lin J, Kissling W, Leucht S. Comparative remission frequencies of schizo-phrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1643-1651.
13. Cassidy CM, Norman R, Manchanda R, et al. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull. 2010;36:1001-1008.
14. Helldin L, Kane JM, Karilampi U, et al. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res. 2006;40:738-745.
15. Helldin L, Kane JM, Karilampi U, et al. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res. 2007;93:160-168.
16. Ciudad A, Alvarez E, Bobes J, et al. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res. 2009;108:214-222.
17. Buckley PF, Harvey PD, Bowie CR, et al. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treat-ment with ziprasidone. Schizophr Res. 2007;94:99-106.
18. Emsley R, Rabinowitz J, Medori R et al. Remission in early psychosis: frequencies, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89:129-139.
19. Kelly DL, Weiner E, Ball MP, et al. Remission in schizophrenia: the relationship to base-line symptoms and changes in symptom domains during a one-year study. J Psychopharmacol. 2009;23:436-441.
20. Opler MGA, Yang LH, Caleo S et al. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry. 2007;7:35.
21. Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005;77:215-227.
22. Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res. 2007;95:143-150.
23. De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res. 2007;92:68-73.
24. Wunderink L, Nienhuis FJ, Sytema S, et al. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull. 2007;33:792-796.
25. Emsley R, Oosthuizen PP, Kidd M, et al. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry. 2006;67:1707-1712.
26. Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res. 2008;106:281-285.
27. Helldin L, Kane JM, Hjärthag F, et al. The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study. Schizophr Res. 2009;115:67-73.
28. Eberhard J, Levander S, Lindström E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry. 2009;50:200-208.
29. Bodén R, Sundström J, Lindström E, et al. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107:232-237.
30. Bobes J, Ciudad A, Alvarez E, et al. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res. 2009;115:58-66.
31. San L, Ciudad A, Alvarez E, et al. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry. 2007;22:490-498.
32. Wunderink L, Sytema S, Nienhuis FJ, et al. Clinical recovery in firstepisode psychosis. Schizophr Bull. 2009;35:362-369.
33. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697.
34. Catty J, Lissouba P, White S, et al. Predictors of employment for people with severe mental illness: results of an international six-centre randomised controlled trial. Br J Psychiatry. 2008;192:224-231.
35. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone--analysis of long-term efficacy. J Psychopharmacol. 2005;19(5 Suppl):15-21.
36. Rossi A, Bagalà A, Del Curatolo V, et al. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009;24:574-583.
37. Caton CL, Hasin DS, Shrout PE, et al. Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophr Bull. 2006;32:618-625.
38. Cohen CI, Pathak R, Ramirez PM, et al. Outcome among community dwelling older adults with schizophrenia: results using five conceptual models. Community Ment Health J. 2009;45:151-156.
39. Lambert M, De Marinis T, Pfeil J, et al. Establishing remission and good clinical func-tioning in schizophrenia: predictors of best outcome with longterm risperidone long-acting injectable treatment. Eur Psychiatry. 2010;25:220-229.
40. Gasquet I, Haro JM, Tcherny-Lessenot S, et al. Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur Psychiatry. 2008;23:491-496.
41. Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115:97-103.
42. Menezes NM, Malla AM, Norman RM, et al. A multi-site Canadian perspective: examin-ing the functional outcome from first-episode psychosis. Acta Psychiatr Scand. 2009;120:138-146.
43. Bachmann S, Bottmer C, Schroder J. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study. Psychopathology. 2008;41:115-123.
44. Petersen L, Thorup A, Øqhlenschlaeger J, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry. 2008;53:660-670.
45. Malla A, Norman R, Schmitz N, et al. Predictors of frequency and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006;36:649-658.
46. Novick D, Haro JM, Suarez D, et al. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl). 2007;191:1015-1022.
47. Lambert M, Naber D, Schacht A, et al. Frequencys and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118:220-229.
48. de Haan L, Nimwegen L, Amelsvoort T, et al. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41:125-128.
49. Crumlish N, Whitty P, Clarke M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry. 2009;194:18-24.
50. Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108:223-230.
51. Emsley R, Chiliza B, Schoeman R. Predictors of long-term outcome in schizophrenia. Curr Op Psychiatry. 2008; 21:173-177.
52. Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor in-sight in patients with schizophrenia. A systematic review. Schizophr Bull. 2007;33:1324-1342.
53. Holthausen EA, Wiersma D, Cahn W, et al. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007;149:71-80.
54. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635-645.
55. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:473-479.
56. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006; 36:1349-1362.
57. Whitty P, Clarke M, McTigue O, et al. Predictors of outcome in firstepisode schizophrenia over the first 4 years of illness. Psychol Med. 2008;38:1141-1146.
58. Rosen K, Garety P. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull. 2005;31:735-750.
59. White C, Stirling J, Hopkins R, et al. Predictors of 10-year outcome of first-episode psychosis. Psychol Med. 2009;39:1447-1456.
60. Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108:223-230.
61. Karow A, Naber D, Lambert M, Moritz S. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry. In press.
62. Lambert M, Eich FX, Schacht M, et al. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand. 2007;115:106-113.
63. Lambert M, Schimmelmann B, Eich FX, et al. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009;42:277-283.
64. Lambert M, Naber D, eds. Current Schizophrenia - 2nd edition. London, UK: Current Medicine Group; 2009:1-156.
65. Schimmelmann B, Conus P, Schacht M, et al. Predictors of service disengagement with treatment in first-admitted adolescents with psychosis. J Am Acad Child Adolesc Psychiatry. 2006;45:990-999.
66. Conus P, Lambert M, Cotton S, et al. Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort. Schizophr Res. In press.
67. Schimmelmann B, Conus P, Edwards J, et al. Diagnostic stability 18-month after a first diagnosis of psychosis. J Clin Psychiatry. 2005;66:1239-1246.
68. Lambert M, Schimmelmann BG, Schacht A, et al. Long-term cluster of subjective well-being in schizophrenia: prediction of cluster affiliation and their predictive value for recovery in 2842 patients followed over 3 years. Schizophr Res. 2009;107:165-172.